The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ).
 
Matthew C Mulroy
No Relationships to Disclose
 
Amy Lauren Cummings
Consulting or Advisory Role - Tempus
Research Funding - Genentech (Inst); Novartis (Inst)
 
Melody A. Mendenhall
No Relationships to Disclose
 
David E. Kanamori
No Relationships to Disclose
 
Andrew V. Nguyen
No Relationships to Disclose
 
David Dae-Young Kim
No Relationships to Disclose
 
William E. Lawler
No Relationships to Disclose
 
Tirrell T. Johnson
No Relationships to Disclose
 
Jennifer Tseng
No Relationships to Disclose
 
Sunil Babu
Employment - Fort Wayne Medical Oncology & Hematology
Stock and Other Ownership Interests - Fort Wayne Medical Oncology & Hematology; Lutheran hospital (I)
Honoraria - Alexion Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; argenx; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Kite, a Gilead company
Speakers' Bureau - Alexion Pharmaceuticals
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); argenx (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Syndax (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Lilly
 
Andrew Bennett Brown
No Relationships to Disclose
 
Shaker R. Dakhil
No Relationships to Disclose
 
Sidharth Anand
Consulting or Advisory Role - Signatera
Travel, Accommodations, Expenses - Curio Science
 
Zev A. Wainberg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Dennis J. Slamon
Leadership - Biomarin
Stock and Other Ownership Interests - Amgen; Amgen; BioMarin; Merck Sharp & Dohme; Pfizer; Seagen; Vertex
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Seagen
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Biomarin; Novartis; Pfizer
 
Edward B. Garon
Consulting or Advisory Role - ABL Bio; Boehringer Ingelheim; Bristol-Myers Squibb; Dracen; Eisai; EMD Serono; GlaxoSmithKline; Merck; Novartis; Sanofi; Shionogi; Xilio Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Jonathan Wade Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences
Speakers' Bureau - Merck
Research Funding - Abbvie (Inst); Advaxis (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca